- Current report filing (8-K)
August 13 2010 - 3:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 9, 2010
Idenix Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-49839
|
|
45-0478605
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
60 Hampshire Street
Cambridge, MA
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
617-995-9800
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
Resignation of Director
Steven Projan resigned from the Board of Directors (the Board) of Idenix Pharmaceuticals, Inc. (the Company),
effective August 11, 2010. Mr. Projan served on the Board as one of the designees of Novartis Pharma AG (Novartis)
under the terms of an Amended and Restated Stockholders Agreement, dated July 27, 2004, between the Company, Novartis
and certain other stockholders of the Company.
Resignation of General Counsel
On August 9, 2010, John F. Weidenbruch tendered notice of his intention to resign as Executive Vice President and
General Counsel of the Company, with such resignation to be effective as of August 31, 2010. Mr. Weidenbruch plans to
join a biopharmaceutical company in the Cambridge, Massachusetts area.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Idenix Pharmaceuticals, Inc.
|
|
|
|
|
|
Date: August 13, 2010
|
|
By:
|
|
/s/ Ronald C. Renaud, Jr.
|
|
|
|
|
Name:
Title:
|
|
Ronald C. Renaud, Jr.
Chief Financial Officer
|
3
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More News Articles